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Hideo Kanemitsu, MD, PhD,b Jian Wang, MD,a Tadashi Ikeda, MD, PhD,a and Masashi Komeda, MD, PhDaObjective: Although left ventricular restoration is effective for treating ischemic car-
diomyopathy caused by left ventricular remodeling and redilation, the initial improve-
ment in left ventricular function is not always sustained. We have reported that the
inhibition of the renin-angiotensin-aldosterone system by angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers is effective in preventing late re-
modeling after left ventricular restoration. However, the effects of spironolactone—an
aldosterone blocker—after left ventricular restoration have not been elucidated.
Methods: Myocardial infarction was induced by ligating the left anterior descending
artery. The rats developed left ventricular aneurysms and underwent left ventricular
restoration by the plication of the left ventricular aneurysm 4 weeks after the ligation.
Thereafter, the rats were randomized into a left ventricular restoration (vehicle) group
and left ventricular restoration with spironolactone (100 mg/kg/d, by mouth) group.
Results: Echocardiography revealed that in the left ventricular restoration with spiro-
nolactone group, late cardiac redilation was significantly attenuated (left ventricular
end-diastolic area: 0.51 6 0.03 cm2 vs 0.63 6 0.03 cm2, P , .05) and late left ven-
tricular function was preserved (fractional area change: 48.8% 6 3.0% vs 35.8% 6
2.4%, P , .01). Hemodynamically, rats in the left ventricular restoration with spiro-
nolactone group exhibited improved systolic function (maximal end-systolic pres-
sure-volume relationship: 0.38 6 0.03 mm Hg/mL vs 0.11 6 0.04 mm Hg/mL, P ,
.01) and diastolic function (t: 18.5 6 1.5 sec vs 23.1 6 1.4 sec, P , .05) than those
in the LVR group. Histologically, interstitial fibrosis in the remote area was signifi-
cantly reduced (5.6%6 1.3% vs 12%6 1.0%, P, .01), and fibrosis around the pled-
gets (near area) was also attenuated in the left ventricular restoration with
spironolactone group. The myocardial messenger ribonucleic acid expressions of
transforming growth factor-b1 and brain natriuretic peptide measured using the
real-time polymerase chain reaction were lower in the left ventricular restoration
with spironolactone group (transforming growth factor-b1: 0.13 6 0.02 vs 0.28 6
0.02, P , .01; brain natriuretic peptide: 0.99 6 0.14 vs 1.54 6 0.18, P , .05).
The systemic blood pressure and heart rate did not differ between the 2 groups.
Conclusion: Spironolactone reduced the gene expression of transforming growth fac-
tor-b1 and brain natriuretic peptide and alleviated not only cardiac redilation but also
the deterioration of left ventricular function late after left ventricular restoration with-
out inducing hypotension, a major side effect of angiotensin-converting enzyme in-
hibitors or angiotensin receptor blocker. Spironolactone is a promising therapeutic
option for alleviating remodeling after left ventricular restoration.
L
eft ventricular restoration (LVR) surgery after myocardial infarction (MI) is
effective as a surgical treatment for left ventricular (LV) aneurysm or ischemic
cardiomyopathy.1-5 However, LV redilation and functional deterioration after
LVR are serious problems.6-8
The renin-angiotensin-aldosterone system (RAAS) has been reported to play an
important role in LV remodeling after MI. We have demonstrated that angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and
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ACEI 5 angiotensin-converting enzyme inhibitor
ARB 5 angiotensin receptor blocker
BNP 5 brain natriuretic peptide
BW 5 body weight
Emax 5 maximal end-systolic pressure-volume
relationship
FAC 5 fractional area change
GADPH 5 glyceraldehyde-3-phosphate dehydrogenase
LV 5 left ventricular
1LV dP/dt 5 maximal rate of LV pressure development
2LV dP/dt 5 maximal rate of LV pressure relaxation
LVEDA 5 left ventricular end-diastolic area
LVESA 5 left ventricular end-systolic area
LVR 5 left ventricular restoration
LVR-Sp 5 left ventricular restoration with
spironolactone
LVW 5 left ventricular weight
MI 5 myocardial infarction
mRNA 5 messenger ribonucleic acid
RAAS 5 renin-angiotensin-aldosterone system
TGF 5 transforming growth factor
atrial natriuretic peptide are effective in preventing LV re-
modeling and improving LV function after LVR in a rat
MI model.9-11 However, in the clinical setting immediately
after LVR, the systemic hypotension and renal damage
caused by these anti-RAAS drugs are detrimental, particu-
larly in high-risk patients with severe LV dysfunction.12
Spironolactone—a mineralocorticoid-receptor antago-
nist—competes with aldosterone, which plays an important
role in the RAAS. Spironolactone prevents the detrimental
effect of aldosterone and, at the same time, rarely influences
the blood pressure.13 Therefore, we tested the hypothesis that
spironolactone alleviates cardiac remodeling and functional
deterioration late after LVR without inducing hypotension.
Materials and Methods
Animals
In this study, we used 7-week-old male Sprague-Dawley rats (Har-
lan Sprague-Dawley, Indianapolis, Ind). All procedures performed
here conformed to the ‘‘Guideline for Animal Experiments’’ of
Kyoto University. All rats were fed with standard rat chow, given
water ad libitum, and housed in a single room of the animal facility
with a 12-hour light/dark cycle with independent ventilation,
temperature, and humidity control.
Surgical Induction of Myocardial Infarction
Murine acute MI was established as previously described.14 Briefly,
under general anesthesia, anterior wall MI was induced by the liga-
tion of the left anterior descending artery using a 6-0 polypropylene
suture near the main pulmonary artery. Rats with an infarction size of
less than 30% of the LV circumference as observed on 2-dimensional
echocardiography were excluded from the study.The Journal of ThLeft Ventricular Restoration Surgery
Four weeks after the ligation of the left anterior descending artery,
LVR surgery was performed in the rats as previously described.14
Briefly, rats with a large MI area underwent rethoracotomy. The bor-
der between the aneurysm and the intact myocardium was identified,
and the aneurysm was plicated with 2 pledgets. Polypropylene
sutures (5-0 Prolene) were passed through the pledget, through the
aneurysm at its border, through the opposite pledget in a horizontal
mattress fashion, and then tied. An additional continuous over-
and-over suture was added to plicate the LV aneurysm completely.
Study Group Profiles
After LVR surgery, the rats were randomly treated with the oral ad-
ministration of spironolactone (100 mg/kg/d, dissolved in 1 mL of
2% ethanol: LVR-Sp group, n 5 14) or vehicle (2% ethanol 1 mL
only: LVR group, n5 14) with a metallic gastric tube. The rationale
of the drug dose depended on previous studies concerning spirono-
lactone.15,16 Concomitantly, we confirmed that 1 mL of 2% ethanol
had no hemodynamic or morphologic influence on the rats. To pro-
vide appropriate frames of reference, echocardiographic data of nor-
mal rats (n 5 12) and rats with MI (n 5 12) were also evaluated.
Systolic Blood Pressure and Heart Rate
Systolic blood pressure and heart rate were measured with a nonin-
vasive computerized Softron tail-cuff system (Softron, Kanagawa,
Japan) without anesthesia, as previously described.7
Echocardiography
Echocardiography was performed before LVR, 1 day after LVR, and
4 weeks after LVR. Before all echocardiographic procedures, the rats
were lightly anesthetized with ether and placed in a supine position.
Transthoracic echocardiography was performed with a 12-MHz
transducer and 2-dimensional echo Doppler system (Sonos 4500;
Hewlett Packard, Andover, Mass). M-mode and 2-dimensional mea-
surements were performed as previously described.10
Hemodynamic Evaluation
All of the rats underwent cardiac catheterization for the measure-
ment of functional parameters 4 weeks after LVR surgery, as previ-
ously described.10 Briefly, general anesthesia was administered to
the rats, and they were ventilated. A micromanometer-tipped cathe-
ter (Millar Instruments, Houston, Tex) was inserted into the right
carotid artery. The catheter was advanced into the aorta and then
into the left ventricle. A 3-French Fogarty balloon catheter (Edwards
Life Science Corp, Irvine, Calif) was inserted via the right femoral
vein into the inferior vena cava for caval occlusion. The maximal
rate of LV pressure development (1LV dP/dt), maximal rate of
LV pressure relaxation (2LV dP/dt), LV end-diastolic pressure,
maximal end-systolic pressure-volume relationship (Emax), and
time constant of isovolumic LV relaxation (tau, t) were calculated
as previously described.17,18
Histopathology
The rats were sacrificed 1 day after cardiac catheterization. Hearts
and lungs were excised and weighed. LVs were sliced into 2-mm
cross sections, perpendicular to the ventricular long axis at the
base of the papillary muscles, and were fixed in 10% buffered for-
malin, embedded in paraffin, mounted on glass slides, and stained
using Picrosirius red. Except for the area that was plicated usingoracic and Cardiovascular Surgery c Volume 136, Number 1 59
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to the pledgets were called the ‘‘near areas,’’ and the other 2 areas
were called the ‘‘remote areas.’’7 The images were viewed using
an Eclipse E600 Nikon (Tokyo, Japan) microscope. The digitally
acquired images were analyzed using the IPLab imaging software
(Version 3.71 for Windows; Scanalytics Inc, Rockville, Md). The
results of the planimetry of myocardial fibrosis were analyzed as
previously described.10 The histopathologic results were analyzed
in a blind manner.
Quantitative Real-time Polymerase Chain Reaction
The remaining LV muscles were stored at 280C until use. The
extraction of messenger ribonucleic acid (mRNA) from tissue
samples and polymerase chain reaction were performed as previ-
ously described.10
The nucleotide sequence for primers and TaqMan probes were as
follows: brain natriuretic peptide (BNP), forward primer: 50-GATC
CAGGAGAGACTTCGAAA-30; reverse primer: 50-CGGTTATC
TTCTGCCCAA-30; TaqMan probe: 50-TCCAAGATGGCACATA
GTTCAAGCTG-30; transforming growth factor (TGF)-b1, forward
primer: 50-GGCAGTGGCGAACCAAG-30; reverse primer: 50-CT
GTCACAAGAGCAGTGAGCA-30; TaqMan probe: 50-AGACG
GAATACAGGGCTTTCGCTTC-30. The TaqMan rodent glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) control reagents
were used to detect rat GAPDH as the internal standard. The expres-
sion levels of the target genes were normalized to the GAPDH level
in each sample.
Statistical Analysis
All data are presented as means 6 standard deviation. To analyze
echocardiographic data, multiple group comparisons were per-
formed using 1-way analysis of variance. In multiple comparisons
among independent groups in which analysis of variance indicated
significant differences, the statistical value was determined accord-
ing to the Bonferroni/Dunn post hoc test. All data comparing LVR
group and LVR-Sp group were analyzed with the Wilcoxon rank-
sum test. Statistical analyses were performed with StatView for
Windows (version 5.0; SAS Institute Inc, Cary, NC).
Results
All of the rats survived LVR surgery. There was no differ-
ence in systolic blood pressure levels between the 2 groups
at 4 weeks after LVR (109.5 6 5.8 mm Hg vs 111.3 6 8.6
mm Hg). The heart rate was higher in the LVR-Sp group
than in the LVR group (367 6 39 beats/min vs 400 6 38
beats/min, respectively). However, this difference was not
statistically significant.
Echocardiography
The 2-dimensional echocardiography data before LVR and 1
day and 4 weeks after LVR are summarized in Table 1. Before
LVR and 1 day after LVR, no differences were observed be-
tween the echocardiographic data of the 2 groups. The akinetic
area was 35%6 6% in the LVR group and 33%6 4% in the
LVR-Sp group. One day after LVR, the left ventricular end-
diastolic area (LVEDA) decreased compared with the preop-
erative values in both groups (from 0.926 0.02 cm2 to 0.32660 The Journal of Thoracic and Cardiovascular Surgery c July0.04 cm2 in the LVR-Sp group [P , .05] and from 0.91 6
0.03 cm2 to 0.34 6 0.03 cm2 in the LVR group [P , .05]).
The left ventricular end-systolic area (LVESA) also decreased
in both groups (from 0.70 6 0.02 cm2 to 0.11 6 0.04 cm2 in
the LVR-Sp group [P , .05] and from 0.66 6 0.03 cm2 to
0.12 6 0.05 cm2 in the LVR group [P , .05]).
Four weeks after LVR, the LVEDA and LVESA values
demonstrated an increase in comparison with the values re-
corded immediately after surgery in the LVR group
(LVEDA: from 0.34 6 0.03 to 0.63 6 0.03 cm2 [P , .05]
and LVESA: from 0.12 6 0.05 to 0.40 6 0.08 cm2 [P ,
.05]). Although the LVEDA and LVESA values also in-
creased in the LVR-Sp group, the LVEDA value was lower
in the LVR-Sp group than in the LVR group at 4 weeks after
LVR (0.51 6 0.03 cm2 vs 0.63 6 0.03 cm2, P , .05).
Immediately after LVR, the fractional area change (FAC)
demonstrated an increase (from 24.2% 6 1.0% to 65.7% 6
3.1% in the LVR-Sp group [P , .05] and from 26.6% 6
1.6% to 66.5% 6 2.6% in the LVR group [P , .05]). The
time course of the FAC is shown in Figure 1. The FAC de-
creased gradually after LVR in both groups. However, the
FAC at 4 weeks after LVR was significantly higher in the
LVR-Sp group than in the LVR group (48.8% 6 3.0% vs
35.8% 6 2.4%, respectively; P , .01).
Hemodynamic Evaluation
The results of cardiac catheterization 4 weeks after LVR are
summarized in Table 2. The LV end-diastolic pressure values
did not differ between the 2 groups (12.7 6 5.9 mm Hg vs
13.4 6 8.1 mm Hg). In the LVR-Sp group, however, the
Emax, 1LV dP/dt, and 2LV dP/dt values were higher than
those in the LVR group; the t value was lower than that in
the LVR group (Emax: 0.38 6 0.03 mm Hg/mL vs 0.11 6
0.04 mm Hg/mL, P , .01; 1LV dP/dt: 6568.7 6 1096.3
mm Hg/sec vs 5212.4 6 590.1 mm Hg/sec, P , .01; 2LV
dP/dt: 4011.9 6 554.6 mm Hg/sec vs 3368.9 6 706.2 mm
Hg/sec, P , .05; and t: 18.5 6 1.5 sec vs 23.1 6 1.4 sec,
P , .05; LVR-Sp vs LVR, respectively).
Heart and Lung Weight
Four weeks after LVR, the body weight (BW) of the rats in the
LVR-Sp group (407.26 52.8 g) was similar to that of the rats
in the LVR group (390.3 6 44.3 g). The left ventricular
weight (LVW) and lung weight normalized to BW were lower
in the LVR-Sp group compared with the LVR group (LVW/
BW: 2.14 6 0.1 g/kg vs 2.96 6 1.2 g/kg, P , .05; lung
weight/BW: 8.66 3.1 g/kg vs 10.96 1.7 g/kg, respectively,
P, .05) (Figure 2). Right ventricular weight/BW did not dif-
fer between the 2 groups (1.16 0.3 for LVR-Sp vs 1.36 0.3
for LVR).
Histopathology
Representative photographs of histopathologic findings are
shown in Figures 3 and 4. The interstitial fibrosis in the remote2008
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CDTABLE 1. Echocardiographic data
Pre-LVR 1 d after LVR 4 wk after LVR
Normal MI LVR LVR-Sp LVR LVR-Sp LVR LVR-Sp
LVEDD(cm) 0.86 6 0.03 1.12 6 0.06 1.08 6 0.05 1.06 6 0.06 0.64 6 0.02z 0.64 6 0.03z 0.95 6 0.02 0.83 6 0.02*
LVESD(cm) 0.52 6 0.05 0.96 6 0.04 0.91 6 0.05 0.90 6 0.05 0.35 6 0.08z 0.35 6 0.11z 0.79 6 0.06 0.68 6 0.06y
LVEDA(cm2) 0.57 6 0.07 0.96 6 0.1 0.91 6 0.03 0.92 6 0.02 0.34 6 0.03z 0.32 6 0.04 0.63 6 0.03 0.51 6 0.03*
LVESA(cm2) 0.21 6 0.06 0.72 6 0.07 0.66 6 0.07 0.70 6 0.08 0.12 6 0.05z 0.11 6 0.04z 0.40 6 0.08 0.35 6 0.10
FAC(%) 63.6 6 1.7 24.9 6 1.5 26.6 6 1.6 24.2 6 1.0 66.5 6 2.6z 65.7 6 3.1z 35.8 6 2.4 48.8 6 3.0y
LVR, Left ventricular restoration; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDA, left ventricular
end-diastolic area; LVESA, left ventricular end-systolic area; FAC, fractional area change. *P , .05. yP , .01 versus LVR. zP , .05 versus pre-LVR state.area was attenuated in the LVR-Sp group (Figure 3). A lower
percentage of myocardial fibrosis in the remote area was
observed in the LVR-Sp group compared with the LVR group
(5.6%6 1.3% vs 12%6 1.0%, respectively, P, .05). In the
LVR group, interstitial fibrosis was thick and partially com-
posed of a reticular structure surrounding the myocardial
fibers. On the other hand, the fibrosis was thin and scattered
among the myocardial fibers in the LVR-Sp group. Severe
fibrosis developed around the pledgets (near area) in the
LVR group (Figure 4). However, the fibrosis around the pled-
gets was attenuated in the LVR-Sp group.
Reverse Transcriptase Polymerase Chain Reaction
The results of reverse transcriptase polymerase chain reaction
are shown in Figure 5. Spironolactone inhibited the expres-
sions of TGF-b1 and BNP mRNA (TGF-b1/GAPDH: 0.13
6 0.02 vs 0.28 6 0.02, P , .005; BNP/GAPDH: 0.99 6
0.14 vs 1.546 0.18,P, .05; LVR-Sp vs LVR, respectively).
Discussion
Major Findings
By using hemodynamic, histologic, and molecular
methods, we showed that spironolactone attenuated car-
Figure 1. The time course of FAC calculated from the echocardio-
graphic data obtained from LVR (closed circles) and LVR-Sp
(closed squares) groups. *P < .05 versus LVR. Values are repre-
sented as mean 6 standard deviation. LVR, Left ventricular resto-
ration; LVR-Sp, left ventricular restoration with spironolactone.The Journal of Thdiac remodeling and preserved systolic and diastolic func-
tion late after LVR. LVEDD and LVEDA values were
lower; FAC, Emax, and 1LV dP/dt values were higher;
and the t value was lower in the LVR-Sp group than in
the LVR group. Lower values of LVW/BW and lung
weight/BW in the LVR-Sp group indicate that spironolac-
tone attenuated LV hypertrophy and lung congestion
induced by LV dysfunction. Histopathologically, spirono-
lactone prevented the accumulation of connective tissue in
both the near and remote areas. The expressions of TGF-
b1 mRNA, which is related to adverse remodeling, and
BNP mRNA, which indicates LV wall stress, were in-
hibited. One of the most impressive results of this study
was that spironolactone did not induce severe hypotension
in the rats exposed to such a critical condition after LVR
surgery.
Renin-Angiotensin-Aldosterone System and Cardiac
Remodeling After Left Ventricular Restoration
LVR is an effective treatment for LV aneurysm and ischemic
cardiomyopathy after MI.1-5 However, several clinical and
experimental studies have reported cardiac redilation and
functional deterioration late after LVR.6-8 Although the pre-
cise mechanism of LV redilation after LVR has not been
fully elucidated, we and others have demonstrated that pro-
gressive fibrosis in areas both near and remote from the
TABLE 2. Results of cardiac catheterization 4 weeks after
left ventricular restoration
LVR LVR-Sp
LVEDP (mm Hg) 13.4 6 8.1 12.7 6 5.9
Emax (mm Hg/mL) 0.11 6 0.04 0.38 6 0.03y
1LV dP/dt (mm Hg/sec) 5212.4 6 590.1 6568.7 6 1096.3y
2LV dP/dt (mm Hg/sec) 3368.9 6 706.2 4011.9 6 554.6*
t (sec) 23.1 6 1.4 18.5 6 1.5*
LVR, Left ventricular restoration; LVR-Sp, Left ventricular restoration with
spironolactone; LVEDP, left ventricular end-diastolic pressure; 1LV dP/dt,
maximal rate of left ventricular pressure development; 2LV dP/dt, maximal
rate of LV pressure relaxation; Emax,maximal end-systolic pressure-volume
relationship. *P , .05. yP , .01 versus LVR. Values are mean 6 standard
deviation.oracic and Cardiovascular Surgery c Volume 136, Number 1 61
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CDFigure 2. LV weight (A) and lung weight
(B) normalized to the BW (gray bar: LVR
group, white bar: LVR-Sp group). yP <
.05 versus LVR. Values are represented
as mean 6 standard deviation. LV, left
ventricular; LVR, left ventricular resto-
ration; LVR-Sp, left ventricular restora-
tion with spironolactone.plicated region is one of the key factors responsible and that
the RAAS plays an important role in an autocrine/paracrine
manner.19 Therefore, the inhibition of the RAAS may be
important in preventing persistent remodeling after the ex-
clusion of the aneurysm by LVR and in reducing postopera-
tive morbidity and mortality.
Spironolactone
A number of clinical and experimental studies have dem-
onstrated the efficacy of spironolactone in the treatment
of heart failure.16,20-23 Nonetheless, other RAAS inhibi-
tors, such as ACEI and/or ARB (rather than spironolac-
tone), are chosen in the clinical setting for the treatment
of patients with chronic heart failure because these drugs
are effective against hypertension, which induces cardiac
hypertrophy and plays an important role in the vicious
cycle of heart failure. However, these antihypertensive
drugs may not be as well tolerated in acute and unstable
settings after LVR surgery as they are in chronic heart
failure.
One of the rationales behind the choice of spironolactone
as a treatment option after LVR was that it does not act as
a vasodilator and rarely induces hypotension.13 In this study,
treatment with spironolactone for 4 weeks did not induce hy-
potension. Although the higher heart rate observed in the rats
treated with spironolactone could be caused by the differ-
ences in the LV output, these differences were not statisti-
cally significant.
Further, recent studies have indicated that the once-
inhibited production of aldosterone often increases and
that the anti-remodeling effects of ACEI and ARB therapy
decrease during their long-term administration (aldosterone
escape phenomenon).24 Although the precise mechanism of
this phenomenon has not been well elucidated, the induc-
tion of angiotensin-converting enzyme, the conversion of
angiotensin II from angiotensin I through enzymatic path-
ways other than angiotensin-converting enzyme (eg, chy-
mase), or both may play important roles. Therefore, some
investigators have suggested that ACEI or ARB treatment
is not adequate, and a combination of ACEI and ARB
with an agent that inhibits aldosterone could be effective
in preventing remodeling.25 The important point in this
study is that spironolactone inhibited the expression of the
gene that was related to adverse remodeling and the severity
Figure 3. Histologic findings. High-
power photomicrographs (3200) of Pic-
rosirius red-stained LV cross-section
obtained from LVR (A) and LVR-Sp (B)
rats. In the LVR group, the interstitial
fibrosis (arrows) partially forms a retic-
ular structure surrounding the myocar-
dial fibers. In the LVR-Sp group, the
fibrosis is thin and scatters among the
myocardial fibers.
62 The Journal of Thoracic and Cardiovascular Surgery c July 2008
Tsukashita et al Surgery for Acquired Cardiovascular Disease
A
CDFigure 4. Low-power photomicro-
graphs (340) of Picrosirius red-stained
LV cross-section obtained from LVR (A)
and LVR-Sp (B) groups. Dense collagen
fiber (arrows) develops around the
pledgets (asterisks) in the LVR group.
Spironolactone attenuated fibrous
accumulation.of heart failure (TGF-b1 and BNP). Moreover, spironolac-
tone inhibited connective tissue aggregation both in the
near and remote areas, and further attenuated LV redilation
and preserved LV function without inducing hypotension.
Clinical Implications
As shown in this study, spironolactone may be well tolerated
in critical and unstable settings immediately after surgery. In
addition, spironolactone can be administered intravenously
in patients who are unable to take drugs orally. We recom-
mend the following with respect to spironolactone therapy.
Spironolactone is the first choice immediately after LVR be-
cause these patients are often in low cardiac output states and
hypotension. ACEIs and/or ARBs should be administered
and titrated after patients recover from such severe conditions
and are able to take drugs orally. The proper drug dose and
timing of administration of each drug should be considered
individually.
Study Limitations
There were several study limitations in the present study.
First, the LVR method used in this study is similar to that
of linear closure but not identical. In the clinical setting,
the endoventricular circular patch plasty technique (first
described by Dor and colleagues) is more widely per-
formed than the linear closure methods. However, the
aneurysm was completely excluded by plication, and we
think that this method adequately simulated clinical
LVR because the LV size decreased and LV function
improved.
Second, we used the dose of 100 mg/kg/d according to the
previous studies that used spironolactone for an animal MI
model. However, in the surgical settings used in the present
study, the plasma renin level might be higher than that in
the MI model. Therefore, if we had used a larger amount of
spironolactone, LV redilatation would have been alleviated
more.
Figure 5. Myocardial expression of
BNP mRNA (A) and TGF-b1 mRNA (B)
in the LVR and LVR-Sp groups 4 weeks
after LVR. Data are normalized to the
GAPDH expression. yP < .05 vs LVR.
zP < .01 versus LVR. Values are repre-
sented as mean 6 standard deviation.
BNP, Brain natriuretic peptide; GAPDH,
glyceraldehyde-3-phosphate dehydro-
genase; TGF, transforming growth fac-
tor; LVR, left ventricular restoration;
LVR-Sp, left ventricular restoration
with spironolactone.
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Spironolactone (an aldosterone blocker) attenuated the
expression of mRNA responsible for cardiac fibrosis, LV
remodeling, and the deterioration in LV function after LVR
without hypotension. Spironolactone is a possible therapeutic
option after LVR.
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